The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advances glycation end products at sites of inflammation
Mm. Anderson et al., The myeloperoxidase system of human phagocytes generates N-epsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advances glycation end products at sites of inflammation, J CLIN INV, 104(1), 1999, pp. 103-113
Reactive aldehydes derived from reducing sugars and peroxidation of lipids
covalently modify proteins and may contribute to oxidative tissue damage. W
e recently described another mechanism for generating reactive aldehydes fr
om free alpha-amino acids. The pathway begins with myeloperoxidase, a heme
enzyme secreted by activated neutrophils. Conversion of alpha-amino acids t
o aldehydes requires hypochlorous acid (HOCl), formed from H2O2 and chlorid
e by myeloperoxidase. When L-serine is the substrate, HOCl generates high y
ields of glycolaldehyde. We now demonstrate that a model protein, ribonucle
ase A (RNase A), exposed to free L-serine and HOCl exhibits the biochemical
hallmarks of advanced glycation end (AGE) products - browning, increased f
luorescence, and cross-linking. Furthermore, N-epsilon-(carboxymethyl)lysin
e (CML), a chemically well-characterized AGE product, was generated on RNas
e A when it was exposed to reagent HOCl-serine, the myeloperoxidase-H2O2-ch
loride system plus L-serine, or activated human neutrophils plus L-serine.
CML production by neutrophils was inhibited by the H2O2 scavenger catalase
and the heme poison azide, implicating myeloperoxidase in the cell-mediated
reaction. CML was also generated on RNase A by a myeloperoxidase-dependent
pathway when neutrophils were activated in a mixture of amino acids. Under
these conditions, we observed both L-serine-dependent and L-serine-indepen
dent pathways of CML formation. The in vivo production of glycolaldehyde an
d other reactive aldehydes by myeloperoxidase may thus play an important pa
thogenic role by generating AGE products and damaging tissues at sites of i
nflammation.